The FDA is reviewing a potential new therapy for sickle cell disease that targets its genetic root. This CRISPR-based gene therapy, which is the first of its type in the United States, has the potential to transform treatment for the largely Black sickle cell patient population. Approval is expected in December, with healthcare experts holding high hopes.
We'll keep you updated on all new application updates and features!